The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD

Philip M. Short; Peter A. Williamson; Douglas H. J. Elder; Samuel I. W. Lipworth; Stuart Schembri; Brian J. Lipworth

doi:10.1378/chest.11-0038

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD

Philip M. Short, Peter A. Williamson, Douglas H. J. Elder, Samuel I. W. Lipworth, Stuart Schembri, Brian J. Lipworth

Research output: Contribution to journal › Article › peer-review

88 Citations (Scopus)

Abstract

Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting ß-agonists (LABAs).

Original language	English
Pages (from-to)	81-86
Number of pages	6
Journal	Chest
Volume	141
Issue number	1
DOIs	https://doi.org/10.1378/chest.11-0038
Publication status	Published - Jan 2012

Keywords

Obstructive pulmonary disease
Trial
Fluticasone
Salmeterol
Combination
Placebo
Asthma

Access to Document

10.1378/chest.11-0038

Cite this

@article{cb85a548d1ab4540b5696e3c5708c9c8,

title = "The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD",

abstract = "Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting {\ss}-agonists (LABAs).",

keywords = "Obstructive pulmonary disease, Trial, Fluticasone, Salmeterol, Combination, Placebo, Asthma",

author = "Short, {Philip M.} and Williamson, {Peter A.} and Elder, {Douglas H. J.} and Lipworth, {Samuel I. W.} and Stuart Schembri and Lipworth, {Brian J.}",

year = "2012",

month = jan,

doi = "10.1378/chest.11-0038",

language = "English",

volume = "141",

pages = "81--86",

journal = "Chest",

issn = "0012-3692",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD

AU - Short, Philip M.

AU - Williamson, Peter A.

AU - Elder, Douglas H. J.

AU - Lipworth, Samuel I. W.

AU - Schembri, Stuart

AU - Lipworth, Brian J.

PY - 2012/1

Y1 - 2012/1

N2 - Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting ß-agonists (LABAs).

AB - Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting ß-agonists (LABAs).

KW - Obstructive pulmonary disease

KW - Trial

KW - Fluticasone

KW - Salmeterol

KW - Combination

KW - Placebo

KW - Asthma

U2 - 10.1378/chest.11-0038

DO - 10.1378/chest.11-0038

M3 - Article

C2 - 21799028

SN - 0012-3692

VL - 141

SP - 81

EP - 86

JO - Chest

JF - Chest

IS - 1

ER -

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD

Abstract

Keywords

Access to Document

Fingerprint

Cite this